Introduction
prophylaxis (HgP)' (Poly Influenzinum combi C200 Influ vac, Vaxigrip, 2013 Vaxigrip, -2014 , and(3) no immunisation.
Influenza is an annualseasonal problem in most countries. It is common for different strains of influenza to be active in successive years. In most Western countries the onset of cooler weather is accompanied by calls by public health officials for people who may be badly affected by the flu to be vaccinated.
The effectiveness of the flu vaccination ranges between lO and 60% according to the Centers for Disease Control in the United States,I and may cause influenza-like symptoms in some people.2 Homeopathic prophylaxis against influenza has been used for decades around the world. While stand-alone studies exist measuring the effectiveness of homeopathic influenza prophylaxis,3 no studies measuring its comparative effectiveness to vaccination have been undertal<en. This paper describes the findings of a prospective observational pilot study which toole place in the Netherlands between October 12, 2013 and February 21 , 2014 compar- ing the effectiveness and safety of three influenza immunisation options in 150 patients aged between 60 and 85 years, of a family physician, including (1) regular flu vaccination (Vaxigrip, 2013 (Vaxigrip, 2014 . (2) a homeopathic flu Method Formal ethics approval was not sought for the in-house pilot study, although standard protocols were followed. In this study posters and a covering letter describing the study were prepared in advance. The posters in both Dutch and English were displayed in the practice of the family doctor located in [he South of the Netherlands a few days before influenza vaccinations scheduled on October 22 and 24, 2013. Recruitment into the study occurred in the following way. Patients in cohort 2 were recruited by GH following advice by the doctor of patients who requested (and usually received) homeopathic flu immunisation. These participants were sent a covering letter and three questionnaires. GH then contacted the participants by telephone, during which consent was requested. In this first interview the consenting participants graded their feeling of well being at that time, and were advised about the scheduled dates for talking the HgP. The dosing schedule consisted of taldng 3 gr of the HgP weekly for the first 3 weel<s, and then 4 gr every 3 wed(s until March 2014.
[t was agreed that 2 months after this phone interview, they would be contacted again by GH in December 2013 for the middle interview, and then again in February 2014 for the final interview. The data from this cohort were collected between October 24, 2013 and February 21, 2014. Results stable 2 shows the average age and the number of males and females in each cohort within the study population. ,- Table 3 shows the incidence of an influenza lille illness at the 2nd and 3rd interview, and whether it was confirmed by the GP (Blag GP). The intensity of the symptoms is classified as being mild, moderate or severe.
-- Table 4 compares the attacl< rates for each option. Note that it was not possible to determine whether participants were exposed to the influenza virus .- Table 5 shows Odds ratio and Chi Squared calculations for the three immunization options.
-.. Table 6 compares the relative risl< associated with each of [he three immunization options at both the 2nd and the 3rd interviews.
-- Fig. 2 shows comparisons between the three immunisation options and three ranldngs of the severity of influenza. stable 7 reports the timing of adverse reactions to vaccination and HgP. It is impossible to know if a reaction that occurred weel<s after an immunization was or was not directly related to the procedure.
-- Table 8 shows a summary of the type and timing of reactions to vaccination. Both of the reported reactions to HgP related to cold/flu lille symptoms. ,- Table 9 shows the percentage of participants in each wellbeing score at each of the three interviews. -- Table 10 shows the reported changes in health at the 2nd and 3rd interviews. The health changes are described graphically in nFig. 3.
Cohort 3: Patients Who Chose to Use No Method of Immunisation against Influenza
Cohort 3 patients were recruited by GH following advice by the doctor of patients who had not requested either vaccination or homeopathic flu immunisation. In the weel< before November 1 . 201 3, this cohort was sent a covering letter with three questionnaires. The premeasurement of cohort 3 was undertal<en by GH by telephone on November 1, 2013 during which consent to participate was obtained. The second interview by telephone by GH followed on December 27, 2013, and the final interview was held via telephone February 21, 2014.
In al1 152 persons were invited to participate and 2 declined. The relevant numbers and dates are shown in - Table I . An outline of the questionnaires used in the survey is shown in - Fig. 1 . Participants were first asl<ed to confirm their immunisation status. Then they were asl<ed whether or not they had contracted an influenza-lil(e illness. If 'yes', the date of the first symptoms was recorded, whether these were confirmed by a doctor and whether the symptoms were mild,
Discussion
The findings of the pilot study will be considered under three subheadings: effectiveness, reactions/safety and well=being. Give a number between 1-10, with lbeing very poor and 10 very well. However, the three cohorts were patients of a singlefamily physician, which should increase the chances of demographic homogeneity.
The comparison between the HgP and the no-immunisation cohort is less clear. The HgP attacl< rate was 0% after 2 months and 5.5% after 4 months. The no-immunisation cohort showed 6.3 and 2.1%, respectively. The smaller numbers clearly limited the generalisability of the comparison.
The larger incidence after 4 months for the HgP cohort may suggest that use of a different remedy for HgP should be considered in future research (e.g., Nosodes or Genus Epidemicus remedies instead of vaccine potencies), or a different potency or dosing regimen. Table 2 Composition of study population; sex/age ReactionsjSafety .- Table 7 reports the number and timing of adverse reactions to vaccination and HgP. There were five times more reactions within the first weel< in the vaccinated cohort compared with the HgP cohort. Over a quarter of vaccinated respondents reported, a reaction within the first weel{ was compared with 5.3% in the HgP cohort.
The type and timing of reactions to vaccination are shown in - 
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Hasselaar et al 123 Table 3 The incidence and severity of influenza Abbreviations: GP, general practitioner; HgP, homeopathic flu prophylaxis; ND, no details Note: This table shows the incidence of an info uenza-lille ill ness at the second and third interviews, and whether it was confirmed by the GP (drag GP)
The intensity of the symptoms is classified as being mild, moderate or severe.
gastrointestinal reactions, and the remainder were reports of muscle aches. weakness, and from one respondent who lost consciousness and collapsed following the vaccination. The two respondents reporting a reaction to HgP described cold and flu-lille symptoms.
obvious explanation is that the effects of winter impacted all cohorts.
The well-being measures in - Table 9 show that the HgP cohort reported the lowest initial measure of well-being, but that their well-being declined less over the 4 months of 'Chi-square is a statistical test commonly used to compare observed data with data we would expect to obtain according to a specific hypothesis. The chi-square test is always testing what scientists call the null hypothesis, which states that there is no significant difference between the expected and observed result. the study than in the other cohorts. Well being in the no-immunisation cohort declined the most. However, this was reversed in ,- Table 10 Brazil, 174)
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